Почетна › Бубрежен карцином (Реналноклеточен карцином) › Њујорк › New York City
Клинички испитувања за Бубрежен карцином (Реналноклеточен карцином) во New York City, NY
27 студии за Бубрежен карцином (Реналноклеточен карцином) бараат учесници на локации во и околу New York City (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Се регрутираФаза 1
- Research Site, New York
- Research Site, New York
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Се регрутираФаза 1
- NEO-811 NYC Site, New York
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Се регрутираФаза 1/2
- Laura and Isaac Perlmutter Cancer Center ( Site 5016), New York
- Memorial Sloan Kettering Cancer Center ( Site 5002), New York
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Се регрутираФаза 1
- Memorial Sloan Kettering Cancer Center, New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Се регрутираФаза 1
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Се регрутираФаза 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Се регрутираНабљудувачка студија
- NYU Langone Medical Center, New York
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Се регрутираФаза 3
- Memorial Sloan Kettering Cancer Center ( Site 0126), New York
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Се регрутираФаза 1/2
- Memorial Sloan Kettering Cancer Center, New York
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Се регрутираФаза 2
- Columbia University Irving Medical Center, New York
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Се регрутираФаза 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Manhattan Eye Ear and Throat Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
- и уште 1
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Се регрутираФаза 1/2
- Icahn School of Medicine at Mount Sinai, New York
- Evelyn H. Lauder Breast and Imaging Center (BAIC), New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
- и уште 1
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Се регрутираФаза 1
- Memorial Sloan Kettering Cancer Center, New York
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Се регрутираФаза 1/2
- Tisch Cancer Institute (TCI), Icahn School of Medicine, New York
- Columbia University, New York
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Се регрутираФаза 3
- Mount Sinai Chelsea, New York
- Mount Sinai Hospital, New York
- Manhattan Eye Ear and Throat Hospital, New York
- и уште 2
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Се регрутира
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Се регрутираФаза 1
- New York Cancer & Blood Specialists, New York
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Се регрутираФаза 1
- Memorial Sloan Kettering Cancer Center, New York
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Се регрутираФаза 1
- Xencor Investigative Site, New York
- Xencor Investigative Site, New York
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Се регрутираФаза 1/2
- NYU Langone Health Perlmutter Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University - The Trustees of Columbia University in the City of New York, New York
- и уште 1
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Се регрутираФаза 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Се регрутираФаза 1
- NYU Laura and Isaac Perlmutter Cancer Center - 34th Street /ID# 257869, New York
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Се регрутираФаза 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Decision Aid (DA) for Renal Patients
Се регрутира
- NYU Langone Health, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Се регрутираФаза 1/2
- NYU Langone Health, New York
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Се регрутираФаза 1/2
- Memorial Sloan-Kettering Cancer Center, New York
Испитувања за Бубрежен карцином (Реналноклеточен карцином) во други градови
- Houston, TX35 студии
- Nashville, TN23 студии
- Dallas, TX23 студии
- St. Louis, MO23 студии
- Los Angeles, CA20 студии
- Boston, MA16 студии
- Baldwin Park, CA16 студии
- Philadelphia, PA15 студии
- Pittsburgh, PA15 студии
- Queens, NY15 студии
- Rochester, MN14 студии
- Cleveland, OH14 студии
Други студии во New York City
- Рак на дојка136 студии
- Рак на бели дробови со не-мали клетки121 студија
- Рак (сите типови)109 студии
- Рак на простата103 студии
- Метастатски карцином93 студии
- Колоректален карцином78 студии
- Карцином на јајниците69 студии
- Рак на бели дробови60 студии
- Множен миелом60 студии
- Карцином на панкреасот60 студии
- Рак на ендометриумот52 студии
- Акутна миелоидна леукемија51 студија
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.